A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Physiological Effects on Liver Structure and Function of an Amino Acid Food Product, AXA1957, in Adolescent Subjects With Fatty Liver
Latest Information Update: 27 Sep 2021
Price :
$35 *
At a glance
- Drugs AXA 1957 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Axcella Health
- 06 May 2020 Status changed from suspended to discontinued, according to an Axcella Health media release.
- 06 May 2020 According to an Axcella Health media release, Given the strength and consistency of data on AXA1125, the company has selected it as product candidate for NASH and have decided that we will not reinitiate this study.
- 23 Mar 2020 Status changed from recruiting to suspended, according to an Axcella Health media release.